Fig. 7

Inhibition or silencing of NTPDase3 increases the amount of osteogenic transcription factor Osterix in 21-day BM-MSC cultures (first subculture) obtained from Pm women to the levels found in younger females. In panel A, shown are typical immunoblots stained for Osterix (52–61 kDa) transcription factor in BM-MSCs from two young (Y1 and 2) and three Pm (Pm1, 2 and 3) women cultured in an osteogenic-inducing medium (i) in the absence or the presence of the NTPDase3 inhibitor, PSB 06126 (3 µM), or (ii) after NTPDase3 gene silencing with lenti-shRNAs encoding for TL313202VD (Seq D; MOI 3) and TL313202VC (Seq C; MOI 3) inhibitory vs. control scramble sequences; either β-Actin (46 kDa) or GAPDH (39 kDa) protein amounts were used as house-keeping gene product standards for normalization purposes. Uncropped full-length gel blots can be found in Additional file 4: Fig. S4. Panel B shows the relative expression of Osterix in BM-MSCs from young females and Pm women submitted or not to NTPDase inhibition with PSB 06126 (3 µM) or to gene silencing with lenti-shRNAs encoding for TL313202VD (Seq D; MOI 3) and TL313202VC (Seq C; MOI 3). Each bar corresponds to the results from a single patient, thus reflecting some inter-individual variability